Abbott Laboratories  

(Public, NYSE:ABT)   Watch this stock  
Find more results for ABT
38.38
0.00 (0.00%)
Real-time:   10:16AM EDT
NYSE real-time data - Disclaimer
Currency in USD
Range 38.14 - 38.50
52 week 32.70 - 40.49
Open 38.26
Vol / Avg. 983,449.00/8.63M
Mkt cap 59.22B
P/E 25.27
Div/yield 0.22/2.29
EPS 1.52
Shares 1.54B
Beta 0.26
Inst. own 70%
Apr 25, 2014
Abbott Annual Shareholder Meeting - 10:00AM EDT - Add to calendar
Apr 16, 2014
Q1 2014 Abbott Earnings Release
Apr 16, 2014
Q1 2014 Abbott Earnings Conference Call - Webcast
Jan 22, 2014
Q4 2013 Abbott Earnings Release
Jan 22, 2014
Q4 2013 Abbott Earnings Conference Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 10.42% 10.91%
Operating margin 13.38% 12.03%
EBITD margin - 20.49%
Return on average assets 5.43% 4.33%
Return on average equity 9.68% 9.18%
Employees 69,000 -
CDP Score - 84 B

Address

C/O TAX DEPT D367 & AP6D 100 Abbott Park Road
ABBOTT PARK, IL 60064-3500
United States - Map
+1-847-9376100 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a portfolio of science-based health care products. Abbott operates in four business segments: diagnostics, medical devices, nutritionals and generic pharmaceuticals. Geographically, 30% of its revenue is generated in the United States; 30% in Western Europe, Canada, Japan and Australia, and 40% in the economies, including India, China, Russia and Brazil. In January 2013, the Company completed the separation of its research-based pharmaceuticals business, which became AbbVie, a new independent biopharmaceutical company. In August 2013, Abbott Laboratories completed its acquisition of OptiMedica Corporation. In August 2013, Abbott Laboratories completed its acquisition of IDEV Technologies.

Officers and directors

Miles D. White Chairman of the Board, Chief Executive Officer
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Thomas C. Freyman Chief Financial Officer, Executive Vice President - Finance
Age: 58
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Hubert L. Allen Executive Vice President, General Counsel, Secretary
Age: 47
Bio & Compensation  - Reuters
Richard W. Ashley Executive Vice President - Corporate Development
Age: 69
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Brian J. Blaser Executive Vice President - Diagnostics Products
Age: 48
Bio & Compensation  - Reuters
John M. Capek Ph.D. Executive Vice President - Medical Devices
Age: 51
Bio & Compensation  - Reuters
Michael J. Warmuth Executive Vice President - Established Pharmaceuticals
Age: 50
Bio & Compensation  - Reuters
Paul K. Magill Senior Vice President, Chief Marketing Officer
Age: 51
Bio & Compensation  - Reuters
Stephen R. Fussell Senior Vice President - Human Resources
Age: 55
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Katherine C. Doyle Senior Vice President - U.S. Nutrition
Bio & Compensation  - Reuters